Global Afatinib Dimaleate Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Afatinib Dimaleate Market Insights, Forecast to 2034
Afatinib dimaleate is an oral molecular targeted drug developed and produced by Boehringer Ingelheim, Germany. It is a TKIs with strong and irreversible dual inhibitory effect on EGFR and HER2, and was approved by THE US FDA in July 2013.It is not only suitable for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion mutation or exon 21 (L858R) replacement mutation, but also a second - and third-line target drug for egFR-TKIS resistance.
Market Analysis and InsightsGlobal Afatinib Dimaleate Market
The global Afatinib Dimaleate market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
Report Includes
This report presents an overview of global market for Afatinib Dimaleate market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Afatinib Dimaleate, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Afatinib Dimaleate, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Afatinib Dimaleate revenue, market share and industry ranking of main companies, data from 2018 to 2024. Identification of the major stakeholders in the global Afatinib Dimaleate market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2034. Evaluation and forecast the market size for Afatinib Dimaleate revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Boehringer Ingelheim Pharmaceuticals, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Cayman Chemical Company, Target Molecule Corp., Frontier Specialty Chemicals, Combi-Blocks and Selleck Chemicals, etc.
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of Afatinib Dimaleate in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Afatinib Dimaleate companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Afatinib Dimaleate revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions
Market Analysis and InsightsGlobal Afatinib Dimaleate Market
The global Afatinib Dimaleate market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
Clinical studies have shown that afatinib dimaleate reduces the risk of both cancer progression and death by 19% compared with first-generation EGFR TKI erlotinib, and significantly improves disease control rates, quality of life, and control of cancer symptoms.Prior to the Approval in China, afatinib has been approved in more than 70 countries for the treatment of PATIENTS with EGFR mutation-positive non-small cell lung cancer, and has become the preferred egFR-targeting drug in many countries.In addition, the drug was approved in 2016 by the US FDA and the European Union respectively for patients with advanced lung squamous cell carcinoma whose disease worsens during or after platinum-based chemotherapy.At present, the drug has been included in the medical insurance in China, and it can be expected that the market size of this product will gradually expand in the future.
Report Includes
This report presents an overview of global market for Afatinib Dimaleate market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Afatinib Dimaleate, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Afatinib Dimaleate, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Afatinib Dimaleate revenue, market share and industry ranking of main companies, data from 2018 to 2024. Identification of the major stakeholders in the global Afatinib Dimaleate market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2034. Evaluation and forecast the market size for Afatinib Dimaleate revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Boehringer Ingelheim Pharmaceuticals, APExBIO Technology LLC, Carbosynth Ltd, Biorbyt, Cayman Chemical Company, Target Molecule Corp., Frontier Specialty Chemicals, Combi-Blocks and Selleck Chemicals, etc.
By Company
Boehringer Ingelheim Pharmaceuticals
APExBIO Technology LLC
Carbosynth Ltd
Biorbyt
Cayman Chemical Company
Target Molecule Corp.
Frontier Specialty Chemicals
Combi-Blocks
Selleck Chemicals
AvaChem Scientific
Advanced ChemBlocks Inc
Glpbio
Nanjing Xize Pharmaceutical Technology Co., Ltd
Shandong Haiwo Biotechnology Co., Ltd
J&K Scientific
Shanghai McLin Biochemical Technology Co., Ltd
Beijing Sjar Technology Development Co., Ltd.
Beijing Wokai Biotechnology Co., Ltd
Ningbo Zhenlei Chemical Co., Ltd.
Beijing Mreda Technology Co., Ltd
MedBio Pharmaceutical Technology Inc
Shanghai Dibai Biotechnology Co., Ltd
Segment by Type
20 mg
30 mg
40 mg
Segment by Application
Treatment of EGFR Mutated Non-Small Cell Lung Cancer
Treatment of NSCLC Patients with Squamous Cell Carcinoma Histologically
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Revenue of Afatinib Dimaleate in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3Detailed analysis of Afatinib Dimaleate companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8China by type and by application revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Afatinib Dimaleate revenue, gross margin, and recent development, etc.
Chapter 12Analyst's Viewpoints/Conclusions
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices